BANK VONTOBEL/CALL/BIOGEN IDEC/370/0.1/17.01.25 | Market Closed - Bid/Ask 11:16:29 17/05/2024 pm IST | After market 12:27:09 am | |||
| 0.06 EUR | -23.08% |
|
0.076 | +26.67% |
| Current month | -11.76% | ||
| 1 month | +9.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.06 | -23.08% |
| 16/24/16 | 0.078 | -53.57% |
| 15/24/15 | 0.168 | +55.56% |
| 14/24/14 | 0.108 | -2.70% |
| 13/24/13 | 0.111 | +32.14% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 11:16 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM9C0S |
| ISIN | DE000VM9C0S6 |
| Date issued | 30/01/2024 |
| Strike | 370 $ |
| Maturity | 17/01/2025 (245 Days) |
| Parity | 10 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.83 € |
|---|---|
| Lowest since issue | 0.027 € |
| Spread | 0.022 € |
| Spread % | 27.85% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Warrants
- Warrant
